-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on ResMed, Raises Price Target to $314

Benzinga·01/30/2026 17:30:09
Listen to the news
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Outperform and raises the price target from $311 to $314.